TCMD Shares Soar 49% on Nimbl™ Launch and Positive Lymphedema Data
By ATTN Desk · Editorial oversight: Sean Han
Introduction
TACTILE SYSTEMS TECHNOLOGY INC (NASDAQ: TCMD) is a Minneapolis-based medical technology company that develops and distributes at-home therapeutic devices for chronic vascular diseases and respiratory conditions. As of November 4, 2023, its shares traded at USD 23.5247, reflecting a daily change of 49.17%, with a trading volume of 640,405.
| Metric | Value |
|---|---|
| Share Price | USD 23.5247 |
| Daily Change | +49.17% |
| Volume | 640,405 |
| Exchange | NASDAQ |
| Ticker | TCMD |
| CIK | 0001104659 |
| Founding Date | January 30, 1995 |
| Headquarters | Minneapolis, Minnesota, USA |
Corporate Structure
Founded in 1995, Tactile Systems Technology Inc is led by CEO Sheri Dodd and employs approximately 992 people (Forbes) within a broader company size range of 1,001–5,000 staff (LinkedIn). The company operates a manufacturing facility in Minnesota and distributes its products across the United States through referrals from physicians, therapists, and nurses. Its offerings include the Flexitouch System, Entre System, Kylee app, AffloVest, and the recently introduced Nimbl™ pneumatic compression controller.
Therapeutic Devices by Susan Wilkinson
Recent Developments
- October 13, 2023: A free webinar offered 1 continuing-education contact hour on advanced management of breast cancer–related lymphedema.
- October 29, 2023: An advanced-level clinician course was conducted on fibrosis assessment and trunk, chest, and breast lymphatic dysfunction.
- October 2023: Tactile Medical partnered with the Foundation for PM&R to support rehabilitation research, awarding Dr. Sharon Bushi a grant for studies related to metastatic cancer patient care.
- October 2023: Mayo Clinic Arizona published data indicating reductions in internal head and neck lymphedema after a single Flexitouch Plus session.
- Product Launch: The Nimbl™ controller—designed to enhance patient mobility during pneumatic compression therapy—was introduced.
Financial and Strategic Analysis
On July 29, 2020, Azvalor Asset Management filed a Schedule 13G with the SEC, disclosing beneficial ownership of 3,652,163 shares (15.347% of outstanding stock). This ownership reflects a significant investment in Tactile Systems Technology. The company’s direct-to-patient model, combined with proprietary pneumatic compression and high-frequency chest wall oscillation technologies, positions it to benefit from current trends in reimbursement for lymphedema and respiratory therapies.
Market Position and Industry Context
Operating in the Health Care Equipment & Services sector, Tactile Medical addresses the treatment needs of an estimated 20 million Americans affected by lymphedema, chronic venous insufficiency, and related conditions. Its product portfolio includes therapies for limb and trunk conditions as well as airway clearance for patients with chronic respiratory and neuromuscular disorders. The U.S. home-based medical device market is continuing to grow, supported by reimbursement policies, and Tactile’s nationwide network of product specialists, trainers, and clinical staff underpins its distribution model.
TL;DR
On November 4, 2023, TCMD shares increased by 49.17% to USD 23.5247 on high trading volume. Events in October included clinician education webinars, a research partnership grant, and reports of clinical data on internal head and neck lymphedema treatments. The launch of the Nimbl™ device aims to improve patient mobility in therapy. With a 15.35% stake held by Azvalor Asset Management (as per the July 29, 2020 SEC filing) and a direct-to-patient distribution model, Tactile Medical is positioned to pursue growth opportunities in home-based vascular and respiratory therapies.